Kailera Therapeutics’ (KLRA) shares soared as high as 68% on Friday following its public debut on Nasdaq, with the obesity treatment developer raising $625 million from the initial public offering (IPO).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
This comes as the Massachusetts-based biopharma company is racing to deliver a once-weekly weight-loss injection to capture gains in the lucrative obesity market. The market is expected to reach $150 billion annually by 2030, according to estimates.
Kailera Eyes Obesity Treatment Market Opportunity
Kailera’s lead drug candidate is ribupatide, known internally as KAI-9531, which is currently in late-stage clinical trials. The treatment is being designed to target GLP-1 and GIP receptors simultaneously — two natural gut hormones that play a key role in regulating appetite and blood sugar.
“Based on clinical data generated to date, we believe ribupatide has the potential to be a category-leading treatment for people living with obesity,” Kailera wrote on its website.
Obesity Treatment Arms Race Accelerates
Kailera’s IPO comes as investments continue to pour massively into obesity treatment research, with investors looking to capture gain in a market dominated by U.S.-based Eli Lilly (LLY) and Danish rival Novo Nordisk (NVO). Most notably, pharma giant Pfizer (PFE) is looking to tap into the market with its recent $10 billion acquisition of Metsera and is eyeing several late-stage trials for its drug candidate.
Top pharma company Amgen (AMGN) is also testing the waters, even as its recent mid-stage trial data showed its obesity drug MariTide helped patients lose a significant amount of weight with lower, less frequent dosing.
Outside these two, several biopharmaceutical firms, such as Artelo Biosciences (ARTL) and Structure Therapeutics (GPCR), are also seeking opportunities in the market.
Which Is the Best Healthcare Stock to Buy?
Of all healthcare stocks highlighted in this article, Structure Therapeutics (GPCR) currently offers the biggest upside of roughly 111%, according to TipRanks’ Stock Comparison tool. This is based on an average price target of $108.34 and comes with a Strong Buy consensus rating.
